Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
Approval based on Phase 3 CheckMate -274 trial results showing that adjuvant treatment with Opdivo significantly reduced patients' risk of disease recurrence or death compared to placebo Opdivo
Opdivo with chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy alone in this patient population; approval based on
Approval based on Phase 3 CheckMate -274 trial results showing that adjuvant treatment with Opdivo significantly reduced patients’ risk of disease recurrence or death compared to placeboOpdivo is now the first and only adjuvant immunotherapy option approved in this setting in the European UnionDecision marks the thi.
Approval is based on positive results from the Phase 3 CheckMate -649 trial Opdivo plus chemotherapy is the first treatment regimen to demonstrate superior overall survival and progression-free survival compared to chemotherapy alone in this patient population Bristol Myers Squibb Receives European Commission Approval for Opdivo + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, .